Rafferty Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-92,224
| Closed | -$1.97M | – | 1083 |
|
|
2023
Q2 | $1.97M | Buy |
92,224
+40,991
| +80% | +$877K | 0.01% | 647 |
|
|
2023
Q1 | $2.07M | Sell |
51,233
-32,181
| -39% | -$1.3M | 0.01% | 602 |
|
|
2022
Q4 | $3.88M | Buy |
83,414
+19,692
| +31% | +$916K | 0.03% | 433 |
|
|
2022
Q3 | $3.31M | Buy |
63,722
+8,526
| +15% | +$442K | 0.04% | 401 |
|
|
2022
Q2 | $2.61M | Sell |
55,196
-2,408
| -4% | -$114K | 0.02% | 414 |
|
|
2022
Q1 | $4.1M | Buy |
57,604
+9,607
| +20% | +$684K | 0.02% | 424 |
|
|
2021
Q4 | $3.59M | Buy |
47,997
+22,444
| +88% | +$1.68M | 0.02% | 496 |
|
|
2021
Q3 | $1.45M | Buy |
25,553
+1,042
| +4% | +$59.2K | 0.01% | 720 |
|
|
2021
Q2 | $1.08M | Sell |
24,511
-9,639
| -28% | -$424K | 0.01% | 859 |
|
|
2021
Q1 | $1.68M | Buy |
34,150
+25,921
| +315% | +$1.28M | 0.01% | 667 |
|
|
2020
Q4 | $346K | Sell |
8,229
-6,579
| -44% | -$277K | ﹤0.01% | 774 |
|
|
2020
Q3 | $678K | Buy |
14,808
+5,759
| +64% | +$264K | 0.01% | 637 |
|
|
2020
Q2 | $454K | Buy |
+9,049
| New | +$454K | 0.01% | 734 |
|
|
2020
Q1 | – | Sell |
-18,470
| Closed | -$1.14M | – | 664 |
|
|
2019
Q4 | $1.14M | Sell |
18,470
-22,569
| -55% | -$1.39M | 0.02% | 523 |
|
|
2019
Q3 | $2.47M | Buy |
41,039
+6,195
| +18% | +$372K | 0.04% | 285 |
|
|
2019
Q2 | $2.94M | Buy |
34,844
+250
| +0.7% | +$21.1K | 0.05% | 259 |
|
|
2019
Q1 | $3.3M | Buy |
+34,594
| New | +$3.3M | 0.05% | 200 |
|